Biotech Analysis Central Preview Series: Unity Biotechnology Inc.

This is a preview blog series on what you can expect when subscribing to my "Biotech Analysis Central" service marketplace. For the full article you must subscribe to my service. This is just an intro of two snippets on the research articles that are written. Thus far, there are about 100+ research reports on both both small-cap and mid-cap biotech stocks with full analysis of the pipeline, catalysts, financials, and clinical trial analysis. If you want to read more then please subscribe to my marketplace service. As always I offer a 2-week free trial just to show you how helpful my service is. You can cancel anytime before the 2-week free trial is up and never be charged a dime.

First Section Of Marketplace Article (This article piece was originally written on July 13, 2020)

The next article I wanted to discuss for the "Biotech Analysis Central Stock Insight Series" is a biotech by the name of Unity Biotechnology Inc. (UBX) The reason why I want to go over this biotech next is because it has a major catalyst coming up in the 2nd half of 2020. This involves results from a phase 2 study using OBX0101 treating patients with osteoarthritis (OA) of the knee. A phase 1 study, which I will go over below, showed some improvements in certain endpoints. The drug was also proven to be safe. The results from this study are expected in Q3 of 2020 (2nd half of 2020 any day now). One big thing I like about this biotech is that it is targeting different indications in the pipeline. By that, I mean a drug is being developed with a different mechanism of action for each one. For Osteoarthritis, the drug OBX0101 is targeting p53/MDM2 proteins. Then there are two drugs that are being worked on to treat multiple types of eye diseases. These drugs are UBX1967 and UBX1325 respectively. They are being developed to treat large market indications like: Age-related macular degeneration, Diabetic macular edema and Diabetic retinopathy. As I stated, the company's pipeline branches out towards other sectors. Like targeting idiopathic pulmonary fibrosis, liver diseases and neurodegenerative diseases. I would say the biggest risk is that all the programs in the pipeline are early. Therefore, If I were to move forward with this biotech it would be with a small speculative position. That's because thus far, there is only one indication in a phase 2 study. Now, if the results turn out good from the phase 2 study, then it will prove that its technology works. The other drugs in the pipeline are still in preclinical studies. The only other advanced drugs would be UBX1967 and UBX1325, which are in IND-enabling studies. In essence, this means they are moving towards phase 1 studies in the coming year.

Conclusion Of Marketplace Article

The Final Verdict is that Unity Biotechnology Inc. is a good speculative biotech. I thought I would share this biotech next because it has a few catalysts expected any day now in the 2nd half of 2020. The most important product in the pipeline is UBX0101, which is being developed to treat patients with Osteoarthritis of the knee. Not only are there 2 readouts expected for this drug, but it targets a large multi-billion dollar market. It is estimated that the osteoarthritis market is set to reach $10.1 billion by 2024. Not only is this indication a large unmet medical need, but these patients need new treatment options. I highlighted the problem that exists with opioids being used to treat these patients. Not only is there addiction, but there are many other side effects associated with these types of opioid drugs. Then you have other multi-billion dollar opportunities like the diabetic retinopathy market, which is expected to reach $10.08 billion by 2025. Which then leads to the diabetic macular edema market, which is set to be around $4.09 billion by 2025. There is a lot of potential here, because Unity is attempting to target the underlying nature of these diseases. That is, it is using its technology to develop drugs that deal with the aging of people. The goal is to attempt to reverse the aging process if possible. The way it does so is by targeting senescent cells in the body, which are responsible for aging. The risk is that this is not yet a fully proven technology. Preliminary evidence I described above, was pretty good, but mixed. However, that may have been attributed to the fact that the Part B study was done in a 4-week period. Which may have been too short. The 12-week study saw some better clinical data. Speaking of which, the phase 2 study to be readout deals with patients being treated for 12 weeks/24 weeks. Unity's technology is unproven, but quite promising if it does end up working out.